Pharming Group Statistics

Total Valuation

Pharming Group has a market cap or net worth of EUR 515.89 million. The enterprise value is 480.14 million.

Market Cap	515.89M
Enterprise Value	480.14M

Important Dates

The next estimated earnings date is Thursday, October 24, 2024.

Earnings Date	Oct 24, 2024
Ex-Dividend Date	n/a

Share Statistics

Pharming Group has 678.35 million shares outstanding. The number of shares has increased by 2.26% in one year.

Shares Outstanding	678.35M
Shares Change (YoY)	+2.26%
Shares Change (QoQ)	+5.16%
Owned by Insiders (%)	2.52%
Owned by Institutions (%)	13.28%
Float	656.63M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.95
PB Ratio	2.50
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-38.61
EV / Sales	1.85
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-79.04

Financial Position

The company has a current ratio of 3.39, with a Debt / Equity ratio of 0.55.

Current Ratio	3.39
Quick Ratio	2.65
Debt / Equity	0.55
Debt / EBITDA	n/a
Debt / FCF	-18.75
Interest Coverage	-1.80

Financial Efficiency

Return on equity (ROE) is -6.33% and return on invested capital (ROIC) is -2.06%.

Return on Equity (ROE)	-6.33%
Return on Assets (ROA)	-1.74%
Return on Capital (ROIC)	-2.06%
Revenue Per Employee	678,126
Profits Per Employee	-32,556
Employee Count	382
Asset Turnover	0.66
Inventory Turnover	0.57

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.54% in the last 52 weeks. The beta is 0.84, so Pharming Group's price volatility has been lower than the market average.

Beta (5Y)	0.84
52-Week Price Change	-32.54%
50-Day Moving Average	0.71
200-Day Moving Average	0.89
Relative Strength Index (RSI)	60.22
Average Volume (20 Days)	5,069,535

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharming Group had revenue of EUR 259.04 million and -12.44 million in losses. Loss per share was -0.02.

Revenue	259.04M
Gross Profit	229.38M
Operating Income	-10.96M
Pretax Income	-14.38M
Net Income	-12.44M
EBITDA	-4.70M
EBIT	-10.96M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 149.63 million in cash and 113.88 million in debt, giving a net cash position of 35.74 million or 0.05 per share.

Cash & Cash Equivalents	149.63M
Total Debt	113.88M
Net Cash	35.74M
Net Cash Per Share	0.05
Equity (Book Value)	206.20M
Book Value Per Share	0.30
Working Capital	177.98M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.38 million and capital expenditures -695,309, giving a free cash flow of -6.07 million.

Operating Cash Flow	-5.38M
Capital Expenditures	-695,309
Free Cash Flow	-6.07M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 88.55%, with operating and profit margins of -4.23% and -4.80%.

Gross Margin	88.55%
Operating Margin	-4.23%
Pretax Margin	-5.55%
Profit Margin	-4.80%
EBITDA Margin	-1.81%
EBIT Margin	-4.23%
FCF Margin	-2.35%

Dividends & Yields

Pharming Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.26%
Shareholder Yield	-2.26%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.

Last Split Date	Mar 5, 2013
Split Type	Reverse
Split Ratio	0.1

Scores

Pharming Group has an Altman Z-Score of 2.52. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.52
Piotroski F-Score	n/a